{"html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fctd-gim.hatenablog.com%2Fentry%2F2022%2F11%2F12%2F162340\" title=\"2022EULAR\u95a2\u7bc0\u30ea\u30a6\u30de\u30c1\u6cbb\u7642\u63a8\u5968 - \u81a0\u539f\u75c5\u30fb\u30ea\u30a6\u30de\u30c1\u4e00\u4eba\u6284\u8aad\u4f1a\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","author_url":"https://blog.hatena.ne.jp/CTD_GIM/","blog_url":"https://ctd-gim.hatenablog.com/","url":"https://ctd-gim.hatenablog.com/entry/2022/11/12/162340","categories":["\u95a2\u7bc0\u30ea\u30a6\u30de\u30c1","\u6cbb\u7642\u85ac","\u30b9\u30c6\u30ed\u30a4\u30c9"],"provider_name":"Hatena Blog","title":"2022EULAR\u95a2\u7bc0\u30ea\u30a6\u30de\u30c1\u6cbb\u7642\u63a8\u5968","height":"190","description":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et alEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateAnnals of the Rheumatic Diseases Published Online First: 10 November 2022. doi: 10.1136/ard-2022-223356 EULAR2022\u2026","provider_url":"https://hatena.blog","image_url":null,"author_name":"CTD_GIM","type":"rich","published":"2022-11-12 16:23:40","blog_title":"\u81a0\u539f\u75c5\u30fb\u30ea\u30a6\u30de\u30c1\u4e00\u4eba\u6284\u8aad\u4f1a","width":"100%","version":"1.0"}